Core Points - Myriad Genetics, Inc. has been recognized on Forbes' list of America's Best Employers 2025, highlighting its status as a leader in genetic and genomic tumor testing and precision medicine [1][2] - The company received positive feedback from its employees, with 84% stating it is a Great Place To Work, which is 27 percentage points higher than the average U.S. company [2] - The selection process for the Forbes list involved an independent survey of over 217,000 U.S. employees from companies with at least 1,000 employees, considering more than 6.5 million employer evaluations [3] Company Overview - Myriad Genetics specializes in genetic tests that assess disease risk and guide treatment decisions, aiming to improve patient care and reduce healthcare costs [6] - The company is dedicated to advancing health and well-being for all through innovative solutions [2][6]

Core Points - Myriad Genetics, Inc. has been recognized on Forbes' list of America's Best Employers 2025, highlighting its status as a leader in genetic and genomic tumor testing and precision medicine [1][2] - The company received positive feedback from its employees, with 84% stating it is a Great Place To Work, which is 27 percentage points higher than the average U.S. company [2] Summary by Sections Company Recognition - Myriad Genetics has been included in the prestigious Forbes list, which is a significant accolade for the company [1] - The recognition is based on an independent survey conducted by Forbes and Statista, involving over 217,000 U.S. employees from companies with at least 1,000 employees [3] Employee Satisfaction - The chief people officer of Myriad Genetics emphasized the company's commitment to innovation and employee empowerment [2] - The high percentage of employees who view the company positively indicates a strong workplace culture [2] Survey Methodology - The selection process for America's Best Employers involved more than 6.5 million employer evaluations, focusing on personal evaluations from employees and public evaluations from friends and family [3] Company Overview - Myriad Genetics specializes in genetic tests that assess disease risk and guide treatment decisions, aiming to improve patient care and reduce healthcare costs [6]

Core Viewpoint - Myriad Genetics, Inc. will hold its fourth quarter and full year 2024 earnings conference call on February 24, 2025, providing a financial overview and business update [1] Upcoming Investor Conferences - Management will participate in three upcoming investor healthcare conferences: - TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 9:50 am ET [4] - Raymond James 46th Annual Institutional Investors Conference on March 4, 2025, at 4:00 pm ET [4] - Leerink Global Healthcare Conference on March 10, 2025, at 2:20 pm ET [4] Company Overview - Myriad Genetics is a leader in genetic and genomic tumor testing and precision medicine, focusing on advancing health and well-being [3] - The company develops genetic tests that assess disease risk and guide treatment decisions, aiming to improve patient care and reduce healthcare costs [3]

Core Insights - Myriad Genetics, Inc. has entered an agreement to enhance education and access to hereditary cancer testing for CancerCARE for Life members, allowing over 1 million individuals to assess their eligibility for the MyRisk test [1][2] - The collaboration aims to strengthen Myriad's Hereditary Cancer testing business, which has been recognized for its significant advances in genomic medicine [2][3] Company Developments - Myriad Genetics' shares experienced a decline of 1.5% following the announcement of the collaboration [3] - The MyRisk Hereditary Cancer Test has been gaining synergies, and it was named one of the top 10 significant advances in genomic medicine by the American Journal of Human Genetics in December 2024 [3][4] - The company has a market capitalization of $1.13 billion and a long-term EPS growth rate of 44%, significantly higher than the industry average of 20% [4] Product Information - MyRisk with RiskScore is the first industry-leading hereditary cancer test that evaluates 48 genes associated with hereditary cancer risk for 11 different cancers [5] - The test provides a five-year and remaining lifetime breast cancer risk assessment when combined with family history and other clinical factors [5] Industry Outlook - The global hereditary cancer testing market was valued at $3.5 billion in 2021 and is projected to grow at a compound annual growth rate of 11.6% through 2031, driven by an increasing geriatric population and rising cancer incidence [8] - The collaboration with CancerCARE is expected to enhance market sentiment towards Myriad Genetics' stock [4] Additional Collaborations - In January, Myriad Genetics partnered with sports broadcaster Hannah Storm, who will serve as an ambassador for the Breast Cancer Risk Assessment Program [9]

Core Insights - Myriad Genetics, Inc. has partnered with INTERLINK Care Management to improve education and access to hereditary cancer testing for CancerCARE for Life members [1][4] - The agreement allows over one million individuals in CancerCARE's network to evaluate their eligibility for the MyRisk test through the MyGeneHistory quiz [2][3] Company Overview - Myriad Genetics is a leader in genetic and genomic tumor testing and precision medicine, focusing on advancing health and well-being through genetic insights [6] - The company offers the MyRisk with RiskScore Hereditary Cancer Test, which evaluates 48 genes linked to hereditary cancer risk and provides personalized risk assessments for various cancers [3][4] Industry Context - CancerCARE for Life is one of the largest cancer prevention and management programs in the U.S., combining education with personalized care to enhance member experiences [5] - The collaboration aims to increase access to genetic screening, enabling patients to make informed decisions regarding their health [4][5]

Core Insights - Myriad Genetics has received two new patents from the United States Patent and Trademark Office, enhancing its capabilities in bringing its tumor-informed, high-definition molecular residual disease (MRD) assay to market [1] - In 2024, Myriad was awarded three patents related to foundational MRD technology and cell-free DNA preparation methods, which enable highly sensitive and specific sequencing-based MRD assays [2] - The company emphasizes that its Precise MRD assay addresses critical questions in cancer treatment, specifically regarding treatment efficacy and cancer recurrence [3] Company Overview - Myriad Genetics is a leader in genetic and tumor genomic testing, focusing on precision medicine to improve health outcomes and reduce healthcare costs [5] - The Precise MRD test utilizes whole-genome sequencing to analyze hundreds to thousands of targeted variants, allowing for sensitive detection of low tumor levels [4] - The company is actively developing its Precise MRD assay in collaboration with academic partners and biopharma companies, with ongoing evaluations in high-impact studies [3][4] Patent Details - The newly issued patents include US patent No. 12,215,391, which pertains to automated methods of MRD analysis, and US patent No. 12,215,392, which relates to patient journey aspects of MRD [7]

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests — Prolaris® Prostate Cancer Test and MyRisk® Hereditary Cancer Test – into Lumea’s digital pathology platform, BxLink™. This collaboration will streamline the ordering and delivery of molecular tests, enabling heal ...

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company’s “Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation” study was awarded SMFM’s “Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics.” The study found that ...

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company's "Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation" study was awarded SMFM's "Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics." The study found that ...

Myriad Genetics, Inc. (MYGN) recently launched a new educational website, Know More Sooner, which provides comprehensive information about reproductive and prenatal genetic testing. The latest launch should bolster the company’s Prenatal business. MYGN Stock Movement Following the NewsFollowing the news, shares of MYGN rose 3.9% to $12.76 yesterday. According to a survey, the majority of women wanted prenatal screening once they understood how genetic testing can provide insights into their pregnancy’s gene ...